Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
J Clin Pharmacol
; 43(4): 379-85, 2003 Apr.
Article
em En
| MEDLINE
| ID: mdl-12723458
ABSTRACT
Plasma concentration profiles of the K+ channel-blocking compound Fampridine were obtained from (1) control subjects (n = 6) following oral administration of doses of 10, 15, 20, and 25 mg and (2) patients with spinal cord injury (SCI) (n = 11) following a single oral dose of 10 mg of an immediate-release formulation. Plasma concentrations were determined using a reversed-phase ion-pair high-performance liquid chromatography (HPLC) assay with ultraviolet light detection employing liquid extraction. The drug was rapidly absorbed with a tmax approximately 1 hour for both groups; tmax was independent of dose. Cmax and AUC0-infinity were linearly related to dose, and t 1/2 was 3 to 4 hours for both groups. There were no obvious differences in the (10-mg) plasma concentration profiles between control subjects and SCI patients. The drug was well tolerated, with only mild and transient side effects of light-headedness, dysesthesias, and dizziness.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Traumatismos da Medula Espinal
/
4-Aminopiridina
/
Bloqueadores dos Canais de Potássio
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article